Fernando Escalante
Leon, CL, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Measurable residual disease assessment in apheresis product from multiple myeloma patients: Correlation with biology, depth of response and survival.
Journal: British journal of haematology
Published: February 26, 2026
Immune biomarkers of increased infection risk in multiple myeloma.
Journal: Blood
Published: September 22, 2025
Immune biomarkers of increased infection risk in multiple myeloma.
Journal: Blood
Published: September 22, 2025
Real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed/ refractory multiple myeloma treated in Europe.
Journal: Haematologica
Published: September 04, 2025
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma.
Journal: Blood cancer journal
Published: August 07, 2025
Clinic-Biological Features and Prognostic Significance of MGUS-Like Myeloma who underwent to Autologous Stem Cell Transplantation.
Journal: Clinical lymphoma, myeloma & leukemia
Published: July 24, 2025
Impact of the Addition of Daratumumab to the Frontline Treatment of Patients with Immunoglobulin Light-Chain Amyloidosis: A Single-Centre Experience.
Journal: Cancers
Published: March 22, 2025
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 22, 2024
Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United States.
Journal: Haematologica
Published: May 20, 2024
Last Updated: 09/26/2026